MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ
1.730
+0.020
+1.17%
After Hours: 1.701 -0.03 -1.71% 19:32 01/08 EST
OPEN
1.700
PREV CLOSE
1.710
HIGH
1.750
LOW
1.680
VOLUME
592.73K
TURNOVER
--
52 WEEK HIGH
4.965
52 WEEK LOW
1.350
MARKET CAP
129.81M
P/E (TTM)
-17.4044
1D
5D
1M
3M
1Y
5Y
1D
Eledon Pharmaceuticals Expects To Present 24-Month Data From 8 Participants In Phase 1 Extension Study Evaluating Tegoprubart In Kidney Transplantation In 2026; Report Other Data From Phase 1, 2 BESTOW Trials
Benzinga · 10h ago
ELEDON PHARMACEUTICALS INC - FUNDS EXPECTED TO SUPPORT OPERATIONS INTO 2Q 2027
Reuters · 10h ago
ELEDON PHARMACEUTICALS HIGHLIGHTS RECENT BUSINESS MILESTONES AND PROVIDES 2026 OUTLOOK
Reuters · 10h ago
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Barchart · 16h ago
Weekly Report: what happened at ELDN last week (1229-0102)?
Weekly Report · 3d ago
Eledon Pharmaceuticals Restructures Stake via Pre-Funded Warrant
TipRanks · 6d ago
Eledon Pharmaceuticals Swaps Shares for Pre-Funded Warrants in Private Exchange
Reuters · 6d ago
Weekly Report: what happened at ELDN last week (1222-1226)?
Weekly Report · 12/29/2025 10:26
More
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Webull offers Eledon Pharmaceuticals Inc stock information, including NASDAQ: ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.